Research programme: vaccines - Sinovac (Dalian) Vaccine Technology

Drug Profile

Research programme: vaccines - Sinovac (Dalian) Vaccine Technology

Alternative Names: Measles virus vaccine - Sinovac Biotech/Dalian Vaccine Technology; Rubella virus vaccine - Sinovac Biotech/Dalian Vaccine Technology

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Sinovac (Dalian) Vaccine Technology
  • Class Vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Measles; Rubella

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Measles(Prevention) in China (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Rubella(Prevention) in China (Parenteral)
  • 05 Apr 2016 Sinovac enters into a technology transfer and supply agreement with GlaxoSmithkline to use GlaxoSmithkline's measles seeds to develop a measles vaccine and combination vaccines containing measles
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top